Nasal mucosal epithelial cells demonstrated reduced apoptotic marker expression including cleaved-CASP-3, cyt-c, NLRP3, ASC, IL-1, IL-18, CASP-1, and cleaved CASP-1, and increased Bcl-2, confirmed by TUNEL-positive apoptotic cell reduction, suggesting an inhibition of anti-apoptotic and anti-inflammatory effects on nasal tissue [219]
Before making any changes to your prescription, speak with your healthcare provider
Nausea ranged from approximately 11% at the lowest 1 mg dose to 64% in some intermediate-dose arms, with about 33% in the 9 mg fixed-dose (highest-efficacy) arm
And on the horizon, with an FDA decision expected by April 10, 2026, is orforglipron, Eli Lilly's next-generation oral GLP-1 that could reshape the entire landscape of medically assisted weight management
Liraglutide | Drugs | BNF NICE